Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19479479 | 0.93 | POLB (0.34) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL12595149 | 0.86 | LMNA (0.38) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL19479659 | 0.84 | ALDH1A1 (0.38) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL12865201 | 0.79 | MEN1 (0.37) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL12595150 | 0.79 | LMNA (0.41) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL12448236 | 0.78 | MEN1 (0.40) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL14893116 | 0.77 | SMN1; SMN2 (0.45) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3389065 | 0.75 | LMNA (0.41) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL17199777 | 0.74 | POLB (0.36) | POLBLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL16423572 | 0.72 | ALDH1A1 (0.60) | ALDH1A1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338849-A1 | COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS | APP, PSEN1, PSEN2 | POLB 3800/4885LMNA 1527/4885ALDH1A1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.